Lacosamide Fresenius Kabi (Lacosamide)

Lacosamide works by selectively enhancing the slow inactivation of voltage‑gated sodium channels in neurons. This stabilises hyper‑excitable membranes, reduces repetitive neuronal firing, and thereby diminishes seizure activity.

The dose of lacosamide is set by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments may be needed for renal impairment or when used with interacting medicines.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Lacosamide’s unique mechanism—enhancing slow inactivation of sodium channels—differs from many traditional antiepileptics that block fast inactivation. This can provide additive seizure control when combined with other agents, and it may have a distinct side‑effect profile, especially regarding cardiac conduction effects.

Lacosamide Fresenius Kabi should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect from light, and avoid freezing or shaking the solution to maintain stability.

The product is supplied as an intravenous solution and is administered by slow infusion into a vein under the supervision of a qualified healthcare professional. The infusion rate and total daily dose are determined by the treating physician.

Serious risks include cardiac arrhythmias such as atrial fibrillation, severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal thoughts or behaviors, respiratory depression, and hepatic injury. Patients should be monitored closely for these events, especially during initiation or dose changes.

Lacosamide should be avoided in patients with known hypersensitivity to the drug, those with severe cardiac conduction disorders without appropriate monitoring, and individuals in whom the risk of serious adverse effects outweighs potential benefits, as determined by a healthcare professional.